bioAffinity Technologies (BIAF) to Release Quarterly Earnings on Wednesday

bioAffinity Technologies (NASDAQ:BIAF) is expected to issue its Q1 2026 results before the market opens on Wednesday, May 20th. Analysts expect bioAffinity Technologies to post earnings of ($2.40) per share and revenue of $1.4830 million for the quarter. Parties can check the company’s upcoming Q1 2026 earning summary page for the latest details on the call scheduled for Friday, May 8, 2026 at 8:30 AM ET.

bioAffinity Technologies (NASDAQ:BIAF) last posted its quarterly earnings data on Friday, May 8th. The company reported ($0.81) EPS for the quarter, beating the consensus estimate of ($2.40) by $1.59. The firm had revenue of $1.35 million during the quarter, compared to analyst estimates of $1.48 million. bioAffinity Technologies had a negative net margin of 280.53% and a negative return on equity of 270.18%.

bioAffinity Technologies Trading Down 4.6%

NASDAQ:BIAF opened at $1.88 on Wednesday. The company has a debt-to-equity ratio of 0.08, a quick ratio of 2.58 and a current ratio of 2.60. The firm has a market cap of $8.46 million, a price-to-earnings ratio of -0.16 and a beta of -1.19. bioAffinity Technologies has a 52 week low of $0.69 and a 52 week high of $15.00. The firm has a 50-day moving average price of $2.65 and a two-hundred day moving average price of $1.88.

Institutional Investors Weigh In On bioAffinity Technologies

A hedge fund recently bought a new stake in bioAffinity Technologies stock. Scientech Research LLC bought a new stake in shares of bioAffinity Technologies, Inc. (NASDAQ:BIAF) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 16,583 shares of the company’s stock, valued at approximately $49,000. Scientech Research LLC owned 0.46% of bioAffinity Technologies as of its most recent SEC filing. Institutional investors own 1.64% of the company’s stock.

Analysts Set New Price Targets

BIAF has been the subject of several analyst reports. Wall Street Zen upgraded shares of bioAffinity Technologies to a “hold” rating in a research note on Saturday, April 4th. Weiss Ratings lowered shares of bioAffinity Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, April 22nd. One investment analyst has rated the stock with a Sell rating, Based on data from MarketBeat, the stock currently has a consensus rating of “Sell”.

About bioAffinity Technologies

bioAffinity Technologies, Inc (NASDAQ: BIAF) is a U.S.-based biotechnology company specializing in the development and commercialization of advanced in vitro diagnostic platforms for oncology. Leveraging proprietary bioaffinity and nanotechnology approaches, bioAffinity’s platforms are designed to isolate and analyze cancer-specific biomarkers from blood, tissue, and other biological samples with high sensitivity and specificity. The company’s core technologies aim to enable earlier detection of solid tumors, improved disease monitoring, and more personalized treatment strategies.

The company’s primary product pipeline includes assays targeting breast cancer and other solid tumor indications.